海辰药业(300584) - 2024 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2024 reached ¥123,965,011.73, an increase of 6.50% year-over-year, while year-to-date revenue decreased by 4.62% to ¥360,497,824.16[2] - Net profit attributable to shareholders for Q3 2024 was ¥3,380,457.70, up 14.69% year-over-year, with a year-to-date net profit of ¥28,116,806.63, reflecting a 25.40% increase[2] - Basic earnings per share for Q3 2024 were ¥0.0282, a rise of 14.63% compared to the same period last year[2] - Total operating revenue for the period was CNY 360,497,824.16, a decrease of 4.06% from CNY 377,948,363.64 in the previous period[13] - Net profit for the period was CNY 28,116,806.63, an increase of 25.06% compared to CNY 22,422,432.46 in the previous period[14] - Basic and diluted earnings per share increased to CNY 0.2343 from CNY 0.1869 in the previous period[15] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period increased significantly by 125.65% to ¥43,945,167.75[6] - The net cash flow from operating activities was $43,945,167.75, an increase from $19,474,793.85 in the previous period, indicating a significant improvement in operational efficiency[17] - The ending cash and cash equivalents balance was $38,197,993.87, down from $72,442,103.38, indicating a decline in liquidity[17] - The cash inflow from operating activities totaled CNY 398,528,192.31, slightly down from CNY 410,474,347.86 in the previous period[16] - The cash outflow for employee compensation was $55,371,255.36, slightly lower than $55,922,425.09 in the previous period, indicating stable labor costs[17] - The net increase in cash and cash equivalents was -$8,624,094.28, compared to -$22,626,020.09, indicating a less severe cash decline[17] Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to ¥1,423,027,127.26, representing a 1.01% increase from the end of the previous year[2] - Total current assets as of September 30, 2024, amount to CNY 335,368,799.83, a decrease from CNY 377,295,829.31 at the beginning of the period[11] - Total liabilities amounted to CNY 412,966,039.91, a decrease from CNY 421,368,242.18 in the previous period[12] - The company’s total liabilities decreased by 86.36% for current liabilities due to the repayment of short-term loans[5] - Total current liabilities decreased to CNY 318,043,036.90 from CNY 400,268,206.38[11] - Total non-current assets increased to CNY 1,087,658,327.43 from CNY 1,031,568,551.09[11] Operational Performance - The company’s operating profit for Q3 2024 was ¥31,361,096.60, reflecting a 30.19% increase year-over-year, attributed to product structure adjustments[5] - Total operating costs decreased to CNY 324,027,907.82, down 7.48% from CNY 350,261,784.04 in the previous period[13] - Research and development expenses rose to CNY 34,268,297.38, an increase of 7.36% from CNY 31,900,346.61 in the previous period[14] - Sales expenses decreased to CNY 150,433,501.51, down 16.43% from CNY 180,025,425.29 in the previous period[14] Shareholder Information - The largest shareholder, Mr. Cao Yuping, and the second-largest shareholder, Ms. Jiang Xiaoqin, hold a combined total of 62,465,219 shares, representing 52.05% of the company's total shares[9] - Total equity attributable to shareholders of the parent company increased to CNY 1,010,061,087.35 from CNY 987,496,138.22 in the previous period[12] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[2]